Amplia Therapeutics Ltd (ASX:ATX)'s Dr John Lambert speaks to Proactive's Andrew Scott following the publication by the Garvan Institute of Medical Research of a key paper describing the fundamental biology underpinning the company’s planned Phase 2 clinical trial in pancreatic cancer patients. The paper titled 'Intravital imaging technology guides FAK-mediated priming in pancreatic cancer precision medicine according to Merlin status' has been published in the high impact peer-reviewed journal 'Science Advances' and further highlights the potential benefits of using a focal adhesion kinase (FAK) inhibitor before administration of standard chemotherapy.
Amplia Therapeutics says Garvan paper has increased its confidence in upcoming Phase 2 trial
